News

The Muscular Dystrophy Association (MDA) has launched its annual MDA Shamrocks campaign, described as the nation’s largest St. Patrick’s Day-themed fundraiser, to support people living with amyotrophic lateral sclerosis (ALS) and other rare neuromuscular diseases. During the campaign, held throughout February and March, thousands of retailers across the…

An assistant professor from the University of Nevada, Las Vegas, whose work focuses on the molecular mechanisms underlying amyotrophic lateral sclerosis (ALS), has been named the first recipient of the MDA Research Momentum Award, a new honor from the Muscular Dystrophy Association (MDA) for early-career scientists. According to an MDA…

Early treatment with PrimeC, an experimental oral treatment being developed by Neurosense Therapeutics, significantly extended survival in people with amyotrophic lateral sclerosis (ALS) by more than 14 months compared with a six-month delay in treatment initiation. That’s according to additional long-term data from PARADIGM (NCT05357950), a completed…

The amyotrophic lateral sclerosis (ALS) community is mourning the loss of Eric Dane, the “Grey’s Anatomy” star who turned his personal battle with the disease into a crusade for a cure. Dane died Thursday at the age of 53, one year after a diagnosis that saw him trade his…

A U.S. biotech company’s experimental oral therapy, neflamapimod, designed to treat age-related brain disorders, has been selected for inclusion in the EXPERTS-ALS platform study, a U.K. initiative aiming to rapidly test potential treatments for amyotrophic lateral sclerosis (ALS). Developer Cervomed announced in a company press release that its treatment…

A triple combination therapy has shown promise for treating sporadic amyotrophic lateral sclerosis (ALS), according to a new study that used cell models of the disease to screen more than 100 therapeutic compounds. The new cell-based model was created from motor neurons, or nerve cells, derived from people with…

The ALS Society of Canada (ALS Canada) and Brain Canada have awarded a combined $515,000 to support four early-career clinicians and researchers advancing care and scientific understanding of amyotrophic lateral sclerosis (ALS). ALS Canada and Brain Canada have been partners since 2014, with early support stemming from…

The U.S.-based advocacy group I AM ALS has secured $313 million in new federal funding for Push for Progress, an effort the nonprofit launched in late 2025 to accelerate research and expand access to treatments for amyotrophic lateral sclerosis (ALS). In a press release announcing the…

No U.S. state earned the highest possible score on the ALS Association‘s annual ALS State Policy Report Cards for policies supporting people with amyotrophic lateral sclerosis (ALS) this year, and several averaged failing grades. The report cards are designed to provide a…

Glycogen, an inflammatory sugar molecule produced by certain gut bacteria, may play a key role in driving amyotrophic lateral sclerosis (ALS), a study found. Treatments to degrade glycogen reduced inflammation and extended survival in an animal model of the disease, and clinical trials to test this approach in people…